Say goodbye to PBMC processing, cold-chain shipping, and multiple assays, and experience the power of a single assay which combines cellular phenotyping directly with the level of activation.
Inflammation plays a critical role in numerous disease processes, including autoimmune disorders, infectious diseases, and immune-related adverse effects in immunotherapy. The ability to accurately assess inflammation is critical for understanding disease mechanisms, monitoring treatment efficacy, and identifying novel therapeutic targets. Traditional cytokine assays often lack the cellular context necessary for fully understanding immune activation and regulation. Inflammatory responses are shaped by intricate cytokine networks and immune cell interactions, which demand a more integrated, high-resolution analytical approach to provide meaningful insights.
Through the development of a proprietary next-generation inflammatory response assay that analyzes 46 markers off the shelf, Aliri can bridge this gap by simultaneously measuring cytokines and immune cell phenotypes, delivering a multi-dimension multi-dimensional dataset to enhance translational research and clinical decision-making.
Audience Takeaways
- How CyTOF works
- Advantages of CyTOF over Flow Cytometry and kit-based LBAs
- Case Study of Aliri’s proprietary Inflammatory Response Assay in Action